ClinicalTrials.gg
RecruitingNCT06162247Updated Mar 3, 2025

Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry)

An observational study in Acute Cardiovascular Disease, Acute Coronary Syndrome and Acute Heart Failure, sponsored by Federico II University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by Federico II University · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Acute Coronary Syndrome by Federico II University — 3 open to participants now, 4 under way, none of them phase 3. Acute Coronary Syndrome · Federico II University.

Started
2023
the only one that year
Observational
6 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Acute Coronary Syndrome by Federico II University, this one is the only one that started in 2023, is one of 6 observational ones, and was the 10th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

3 of the 10 studies in Acute Coronary Syndrome by Federico II University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Acute Coronary Syndrome by Federico II University, or all of them as a file.
02

Study summary

This protocol proposes to prospectively evaluate current epidemiology, pharmacologic and invasive management and clinical outcomes of patients with acute cardiovascular diseases admitted at our ICCU.

Read the detailed description

This study is designed as a single-center, investigator-initiated prospective observational study. Our ICCU is located at the Department of "Scienze Cardiovascolari, Diagnostica per Immagini, e Rete Tempo Dipendente delle Emergenze Cardiovascolari" of the Azienda Ospedaliera Universitaria Federico II. All scientific activities are performed in the Department of Advanced Biomedical Sciences of the University of Naples Federico II.

This is a prospective observational study which does not include pharmacologic or invasive treatments different from daily and guideline-directed management, but only collects data of patients for research purposes, therefore no specific treatments or procedures are included in this research protocol.

The Clinical Trial Unit at the University of Naples "Federico II" will oversee all study procedures and data management. The study data will be anonymized and managed using REDCap electronic data capture, which is hosted at the University of Naples "Federico II".

Once the patient is admitted to our ICCU, the informed consent will be signed and all data will be collected: demographic, clinical, procedural, therapeutic, and outcome data.

Clinical outcomes will be assessed in the in-hospital period, at 30 days, at 1-year and at the longest available follow-up (telephone or follow-up visit).

Main clinical outcomes will be adjudicated by an independent clinical events committee (CEC).

03

Conditions studied

  • Acute Cardiovascular Disease
  • Acute Coronary Syndrome
  • Acute Heart Failure
  • Cardiogenic Shock
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patients with acute cardiovascular diseases admitted at our ICCU will be eligible for inclusion in the study, and only those not providing consent to data collection will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute cardiovascular disease admitted at our ICCU
  2. Age ≥18 years;
  3. Written .

Exclusion criteria

Exclusion Criteria:

  1. Patients not providing consent to data collection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Number of patients with all-cause mortality

    Time frame: 30 days, 1 year

  2. Cardiovascular mortality

    Number of patients with cardiovascular mortality

    Time frame: 30 days, 1 year

  3. Myocardial infarction

    Number of patients with myocardial infarction

    Time frame: 30 days, 1 year

  4. Stent thrombosis

    Number of patients with stent thrombosis

    Time frame: 30 days, 1 year

  5. Stroke

    Number of patients with stroke

    Time frame: 30 days, 1 year

  6. Heart Failure

    Number of patients with heart failure

    Time frame: 30 days, 1 year

  7. Hospitalization for heart failure

    Number of patients with hospitalization for heart failure

    Time frame: 30 days, 1 year

  8. Bleeding

    Number of patients with bleeding

    Time frame: 30 days, 1 year

  9. Acute kidney injury

    Number of patients with acute kidney injury

    Time frame: 30 days, 1 year

  10. Target vessel revascularization

    Number of patients with target vessel revascularization

    Time frame: 30 days, 1 year

  11. Target lesion revascularization

    Number of patients with target lesion revascularization

    Time frame: 30 days, 1 year

  12. Hospital length of stay

    Duration of hospitalization in days

    Time frame: 0 to 30 days (or more depending on diration of hospitalization)

  13. Metrics of diuretic response and decongestion

    Diuresis quantification, weight loss, decongestion score, etc.

    Time frame: 0 to 30 days (or more depending on diration of hospitalization)

  14. Poor neurologic outcomes

    Number of patients with poor neurologic outcomes

    Time frame: 30 days, 1 year

  15. ICCU length of stay

    Duration of ICCU hospitalization in days

    Time frame: 0 to 30 days (or more depending on diration of hospitalization)

  16. Metrics of need for mechanical circulatory support and vasopressors/inotropes

    Need for MCS, MCS type and duration; need for vasopressors/inotropes, vasopressors/inotropes types and duration

    Time frame: 0 to 30 days (or more depending on diration of hospitalization)

  17. Quality of life

    Quality of life assessment by various scores or questionnaires

    Time frame: 30 days, 1 year

07

Study locations

1 of 1 sites recruiting
  • Department of Advanced Biomedical Sciences, University Federico II of Naples
    Napoli, 80131, Italy
    Recruiting
08

References and documents

Publications

  • Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Juni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191. No abstract available. PubMed 37622654 ↗
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195. No abstract available. PubMed 37622666 ↗
  • Leonardi S, Montalto C, Carrara G, Casella G, Grosseto D, Galazzi M, Repetto A, Tua L, Portolan M, Ottani F, Galvani M, Gentile L, Cardelli LS, De Servi S, Antonelli A, De Ferrari GM, Visconti LO, Campo G; ACS Clinical Governance Programme Investigators. Clinical governance of patients with acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2022 Nov 30;11(11):797-805. doi: 10.1093/ehjacc/zuac106. PubMed 36124872 ↗
  • Nadarajah R, Ludman P, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP; NSTEMI Investigators. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. Eur Heart J Qual Care Clin Outcomes. 2022 Dec 13;9(1):8-15. doi: 10.1093/ehjqcco/qcac067. PubMed 36259751 ↗
  • De Filippo O, D'Ascenzo F, Wanha W, Leonardi S, Raposeiras Roubin S, Fabris E, Truffa Giachet A, Huczek Z, Gaibazzi N, Ielasi A, Cortese B, Borin A, Nunez-Gil IJ, Ugo F, Marengo G, Bianco M, Barbieri L, Marchini F, Desperak P, Melendo-Viu M, Montalto C, Bruno F, Mancone M, Ferrandez-Escarabajal M, Morici N, Scaglione M, Tuttolomondo D, Gasior M, Mazurek M, Gallone G, Campo G, Wojakowski W, Abu Assi E, Sinagra G, de Ferrari GM. IncidenCe and predictOrs of heaRt fAiLure after acute coronarY Syndrome: The CORALYS registry. Int J Cardiol. 2023 Jan 1;370:35-42. doi: 10.1016/j.ijcard.2022.10.146. Epub 2022 Oct 25. PubMed 36306949 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2033, 120 months after the start.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 120 months is above that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2023
First posted
Dec 8, 2023
StartActual
Nov 20, 2023
Primary completionEst.
Nov 20, 2033
CompletionEst.
Nov 20, 2033
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06162247
Responsible party
Giuseppe Gargiulo (Associate Professor, Federico II University) — Principal investigator
First posted
Dec 8, 2023
Start date
Nov 20, 2023
Primary completion
Nov 20, 2033 (estimated)
Completion
Nov 20, 2033 (estimated)
Last update
Mar 3, 2025

Study contacts

Giuseppe Gargiulo, MD, PhD
Contact
giuseppe.gargiulo1@unina.it
+39-7462253
Giovanni Esposito, MD, PhD
Contact
espogiov@unina.it
+39-7463075
Giuseppe Gargiulo, MD, PhD
principal investigator · Department of Advanced Biomedical Sciences
Giovanni Esposito, MD, PhD
study chair · Department of Advanced Biomedical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion